Yangzhou Aurisco Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Aurisco Pharmaceutical Co.,Ltd.
October 28, 2020
Share
Yangzhou Aurisco Pharmaceutical Co., Ltd. announced that it will receive CNY 200,000,000 in an equity round of funding on October 29, 2020. The transaction will include participation from returning investor Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) to retain its 100% stake in the company. Post completion of the transaction, the capital of the company will increase from CNY 200,000,000 to CNY 400,000,000. The transaction has been approved by the board of directors of Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) in the third meeting of the second board of directors and the third meeting of the second board of supervisors.
Aurisco Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company distributes its products in domestic market and to overseas markets.
AURISCO PHARMACEUTICAL CO.,LTD. 
